Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 5/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | GLA | P06280 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9925517 | 0.79 | KDM4E (0.47) | ALDH1A1KDM4EMAPTNPSR1GAA | |
| SCHEMBL22519132 | 0.79 | KDM4E (0.55) | ALDH1A1KDM4EMAPTNPSR1GAA | |
| SCHEMBL29953452 | 0.79 | PTGS1 (0.54) | ALDH1A1KDM4EMAPTNPSR1GAA | |
| SCHEMBL13456146 | 0.79 | KDM4E (0.47) | ALDH1A1KDM4EMAPTNPSR1GAA | |
| SCHEMBL870880 | 0.79 | ALDH1A1 (0.55) | ALDH1A1KDM4EMAPTNPSR1GAA | |
| SCHEMBL31423761 | 0.78 | HSD17B10 (0.50) | ALDH1A1KDM4EMAPTNPSR1GAA | |
| SCHEMBL28570789 | 0.76 | HSP90AA1 (0.47) | ALDH1A1KDM4EMAPTNPSR1GAA | |
| SCHEMBL3315853 | 0.75 | KDM4E (0.56) | ALDH1A1KDM4EMAPTNPSR1GAA | |
| SCHEMBL13144230 | 0.75 | ALDH1A1 (0.44) | ALDH1A1KDM4EMAPTNPSR1GAA | |
| SCHEMBL890634 | 0.75 | MAPT (0.55) | ALDH1A1KDM4EMAPTNPSR1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11780837-B2 | CXCR4 inhibitors and uses thereof | X4 PHARMACEUTICALS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780837-B2 | CXCR4 inhibitors and uses thereof | X4 PHARMACEUTICALS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11306088-B2 | CXCR4 inhibitors and uses thereof | X4 PHARMACEUTICALS, INC. (US) | 2022-04-19 | — | — | US | disclosed |
| EP-3808748-A1 | SUBSTITUTED PIPERIDINES AS CXCR4-INHIBITORS | X4 Pharmaceuticals, Inc. (US) | 2021-04-21 | — | — | EP | disclosed |
| US-20210047320-A1 | CXCR4 INHIBITORS AND USES THEREOF | X4 PHARMACEUTICALS, INC. | 2021-02-18 | — | — | US | disclosed |
| EP-3471727-B1 | CXCR4 INHIBITORS AND USES THEREOF | X4 PHARMACEUTICALS INC (US) | 2020-12-09 | — | — | EP | disclosed |
| US-10759796-B2 | CXCR4 inhibitors and uses thereof | X4 PHARMACEUTICALS, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| US-20200123150-A1 | CXCR4 INHIBITORS AND USES THEREOF | X4 PHARMACEUTICALS, INC. | 2020-04-23 | — | — | US | disclosed |
| EP-1984376-A4 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2009-04-08 | — | — | EP | disclosed |
| EP-1984376-A2 | CHEMICAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007087549-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10759796-B2 | CXCR4 inhibitors and uses thereof | CXCR4, CXCL12, CXCR3 | ALDH1A1 1512/4885KDM4E 3366/4885MAPT 4104/4885 |
| US-20210047320-A1 | CXCR4 INHIBITORS AND USES THEREOF | CXCR4, CXCL12, CXCR3 | ALDH1A1 1512/4885KDM4E 3366/4885MAPT 4104/4885 |
| US-11780837-B2 | CXCR4 inhibitors and uses thereof | CXCR4, CXCL12, CXCR3 | ALDH1A1 1512/4885KDM4E 3366/4885MAPT 4104/4885 |
| US-20200123150-A1 | CXCR4 INHIBITORS AND USES THEREOF | CXCR4, CXCL12, CXCR3 | ALDH1A1 1512/4885KDM4E 3366/4885MAPT 4104/4885 |
| US-11306088-B2 | CXCR4 inhibitors and uses thereof | CXCR4, CXCL12, CXCR3 | ALDH1A1 1512/4885KDM4E 3366/4885MAPT 4104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.